Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Bumetanide in congestive heart failure

C Kourouklis, O Christensen, D Augoustakis

    Current Medical Research and Opinion
    |January 1, 1976
    PubMed
    Summary

    Bumetanide effectively treats congestive heart failure by promoting significant diuresis and electrolyte excretion. This new diuretic demonstrated comparable efficacy to frusemide in managing fluid balance and electrolyte levels.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    The reaction of the tubercle bacillus to chemotherapeutic agents.

    Rozhledy v tuberkulose·2014
    Same author

    Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study.

    British journal of cancer·2012
    Same author

    Phase I evaluation of telatinib, a VEGF receptor tyrosine kinase inhibitor, in combination with bevacizumab in subjects with advanced solid tumors.

    Annals of oncology : official journal of the European Society for Medical Oncology·2011
    Same author

    Combination of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma: results from a phase I extension trial.

    European journal of cancer (Oxford, England : 1990)·2008
    Same author

    Treatment with azathioprine and cyclic methylprednisolone has little or no effect on bioactivity in anti-interferon beta antibody-positive patients with multiple sclerosis.

    Multiple sclerosis (Houndmills, Basingstoke, England)·2008
    Same author

    Phase I dose escalation study of telatinib (BAY 57-9352) in patients with advanced solid tumours.

    British journal of cancer·2008

    Area of Science:

    • Pharmacology
    • Nephrology
    • Cardiology

    Background:

    • Congestive heart failure (CHF) management often requires potent diuretics.
    • Understanding the efficacy and safety of novel diuretics is crucial for improving patient outcomes.

    Purpose of the Study:

    • To evaluate the efficacy and effects of bumetanide in patients with congestive heart failure.
    • To compare bumetanide with placebo and frusemide in a crossover study.

    Main Methods:

    • Twenty patients with CHF received bumetanide (1-3 mg daily).
    • Electrolyte levels and diuresis were monitored over 3 and 8 days.
    • A crossover study compared bumetanide, frusemide, and placebo in 10 patients.

    Main Results:

    • Bumetanide significantly increased diuresis and excretion of sodium, potassium, and chloride.
    • Serum electrolyte levels decreased, correlating with drug dosage.
    • Hypochloraemia and mild metabolic alkalosis were observed.
    • Bumetanide showed comparable effects to frusemide on water excretion and electrolytes.

    Conclusions:

    • Bumetanide is an effective diuretic for managing congestive heart failure.
    • Its effects on water and electrolyte balance are dose-dependent.
    • Bumetanide presents a viable alternative to frusemide in CHF treatment.

    Related Experiment Videos